Class / Patent application number | Description | Number of patent applications / Date published |
424100530 | Attachment via an added element (e.g., bifunctional compound or coordinate, coupling agent, spacer compound, bridging compound, conjugated chelate) | 54 |
20080267865 | Targeting of Erb Antigens - A conjugate comprising
| 10-30-2008 |
20080279768 | Bifunctional Metal Chelating Conjugates - The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostics or therapeutic agents. Specifically, conjugates of the present invention include a carrier, a metal coordinating moiety, and a urea linkage chemically linking the metal coordinating moiety to the carrier. The carrier is generally utilized for targeting the conjugate to a biological tissue or organ. | 11-13-2008 |
20080305038 | Transport of Nano-and Macromolecular Structures Into Cytoplasm and Nucleus of Cells - The present invention refers to novel conjugate molecules and their use or the transport of nano- and macromolecular structures into cells and/or the nucleus. More particularly, the present invention refers to conjugate molecules containing a carrier, preferably thiopyridyl moieties, and a cargo moiety. Thereby, the thiopyridyl moiety is bound to the cargo moiety to act as a carrier, particularly for efficient intracellular and/or intranuclear delivery of drugs, nano-or macromolecular structures, etc. The novel conjugate molecules are provided for the manufacture of a medicament for gene therapy, apoptosis, or for the treatment of diseases such as cancer, autoimmune diseases or infectious diseases. | 12-11-2008 |
20090098046 | Combination Cancer Therapy with Anti-PSMA Antibodies - This invention includes compositions and methods for combination cancer treatments, particularly involving at least one cytotoxic agent used in combination with an anti-PSMA monoclonal antibody. | 04-16-2009 |
20090280057 | Combination of Intercalating Organometallic Complexes and Tumor Seeking Biomolecules for DNA Cleavage and Radiotherapy - The invention relates to molecules for treatment and diagnosis of tumors and malignancies, comprising a tumor seeking biomolecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is preferably a radioactive metal, to the use of these molecules and to therapeutic and diagnostic compositions containing them. | 11-12-2009 |
20090304581 | Single wall nanotube constructs and uses therefor - The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs. | 12-10-2009 |
20100104511 | METHODS AND COMPOSITIONS USING CHELATOR-ANTIBODY CONJUGATES - Disclosed are pharmaceutical compositions that include a chelator and an antibody directed against a phosphorylation site of a protein, wherein the antibody is conjugated to the chelator to form a chelator-antibody conjugate. For example, the antibody may recognize a phosphorylated tyrosine residue or a phosphorylated serine residue of a cell surface receptor. Also disclosed are methods of synthesizing a radiolabeled chelator-antibody conjugate, wherein the antibody is directed against a phosphorylation site of a protein. Also disclosed are methods for imaging a site in a subject that involve administering to the subject an effective amount of a composition that includes a valent metal ion-labeled chelator-antibody conjugate, wherein the antibody is an antibody directed against a phosphorylation site of a protein, and detecting a radioactive signal from the site in the subject following administration of an effective amount of the composition. The method of imaging can be applied in diagnosing a tumor, such as a tumor that can be responsive to therapy using a tyrosine kinase inhibitor, and in the treatment of a tumor, such as by targeting therapy to cell surface receptors that include phosphorylation sites. | 04-29-2010 |
20100196267 | Humanized L243 Antibodies - Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided. | 08-05-2010 |
20100254899 | RADIOLABELED AFFIBODY MOLECULES - The invention provides a radiolabeled affibody molecule comprising a fragment of an IgG-binding domain of protein A from | 10-07-2010 |
20100310454 | COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND /OR THEIR CANCEROUS COUNTERPART - The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof. | 12-09-2010 |
20110014120 | TRIFUNCTIONAL IMAGING AGENT FOR MONOCLONAL ANTIBODY TUMOR-TARGETED IMAGING - The present invention relates to trifunctional imaging agents that include an antibody for cell targeting, as well as a chelating moiety for sequestering radioisotopes and a fluorescing moiety for imaging. The invention also provides methods using the conjugates for medical diagnostic imaging. | 01-20-2011 |
20120039800 | Platinum Acridine Anti-Cancer Compounds And Methods Thereof - Acridine containing cisplatin compounds are disclosed that show greater efficacy against cancer than other cisplatin compounds. | 02-16-2012 |
20120076727 | In Vivo Copper-Free Click Chemistry for Delivery of Therapeutic and/or Diagnostic Agents - The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for | 03-29-2012 |
20120134920 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of | 05-31-2012 |
20120201752 | FOXC1 ANTIBODIES AND METHODS OF THEIR USE - In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided. | 08-09-2012 |
20120219495 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF - Provided are a cross-bridged tetraaza macrocyclic compound of a novel structure that can be used, for example, as a contrast agent for diagnostic imaging or a radiopharmaceutical and a method for preparing the same. | 08-30-2012 |
20120244069 | HUMAN MONOCLONAL ANTIBODIES AGAINST CD25 - Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 09-27-2012 |
20120258042 | COMBINED USE OF TGF-B SIGNALING INHIBITOR AND ANTITUMOR AGENT - The combined use of a TGF-β signaling inhibitor and an antitumor active substance or an imaging agent modified by a drug-encapsulating macromolecular micelle, or the like, is provided. The selective delivery capability of the antitumor active substance or the imaging agent to the target is improved, increasing the antitumoral activity in the target. | 10-11-2012 |
20120282178 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of | 11-08-2012 |
20120301396 | RADIOIMMUNOCONJUGATES AND USES THEREOF - The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer—and in particular B-cell malignancies—are aspects of the present invention. | 11-29-2012 |
20130156695 | USE OF ZCYTOR17 LIGAND ANTAGONISTS FOR TREATING INFLAMMATORY DISEASES - The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 06-20-2013 |
20130183235 | ALPHA-EMITTING COMPLEXES - The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes. | 07-18-2013 |
20130189184 | PRETARGETING KIT, METHOD AND AGENTS USED THEREIN - Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has one or more axial substituents. | 07-25-2013 |
20130272958 | ANTI-CEACAM6 ANTIBODIES AND USES THEREOF - The present invention relates to isolated or purified antibodies or fragments thereof specific for CEACAM6 and their use as therapeutic or diagnostic tools. Specifically, the present invention is directed to antibodies or fragments thereof specific for a linear epitope of CEACAM6. In vivo and in vitro methods of diagnosis as well as therapeutic methods are also described. | 10-17-2013 |
20130315821 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of | 11-28-2013 |
20130323169 | THIOL-ENE CLICK CHEMISTRY FOR DRUG CONJUGATES - The present invention relates to linker molecules that readily conjugate cellular recognition ligand at one end and drug payload at the other, and are useful in treating or preventing cancer, an autoimmune disease, an inflammatory condition, a central nervous system disorder or an infection. The linker inker molecules of the invention are represented by Formula I, II and III; Linker-Drug compounds represented by Formula IV, V and VI; and Ligand-Linker-Drug conjugates represented by Formula VII, VIII and IX: | 12-05-2013 |
20140017168 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of | 01-16-2014 |
20140086831 | Single Wall Nanotube Constructs and Uses Thereof - The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs. | 03-27-2014 |
20140093450 | PRETARGETING KIT FOR IMAGING OR THERAPY COMPRISING A TRANS-CYCLOOCTENE DIENOPHILE AND A DIENE - Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has a flattened structure as a result of the position of at least two exocyclic bonds. | 04-03-2014 |
20140099260 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 04-10-2014 |
20140147384 | RADIOIMMUNOCONJUGATES AND USES THEREOF - The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer and in particular B cell malignancies are aspects of the present invention. | 05-29-2014 |
20140219914 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 08-07-2014 |
20140255305 | IMMUNO IMAGING AGENT FOR USE WITH ANTIBODY-DRUG CONJUGATE THERAPY - The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6. | 09-11-2014 |
20140308205 | TRIFUNCTIONAL AND COMPLETELY CLEARABLE SPECIFIC TARGETING AGENTS AND METHODS THEREOF - The invention provides a novel trifunctional targeting construct and related compositions and methods that are useful in therapeutic, diagnostic (including imaging) of various biological and/or pathological conditions and diseases such as cancers and diabetes. The trifunctional targeting construct of the invention provides enhanced clearing step and reduced non-specific background via complete clearance of undesired antibody conjugates. | 10-16-2014 |
20140328754 | RADIOACTIVE METAL-LABELED ANTI-CADHERIN ANTIBODY - A radioactive metal-labeled anti-cadherin antibody which is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent. | 11-06-2014 |
20140369927 | Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases - Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD22 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. | 12-18-2014 |
20150023871 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 01-22-2015 |
20150050210 | PHARMACEUTICAL FORMULATION COMPRISING BENDAMUSTINE - The present invention is related to the field of pharmaceutical compositions for the treatment of various disease states, particularly neoplastic diseases and autoimmune diseases. It especially relates to the oral application of bendamustine and its derivatives. The invention further relates to a process for preparing a pharmaceutical composition which comprises bendamustine and its derivatives prepared by hot melt extrusion using pharmaceutically acceptable excipients. The invention also relates to such pharmaceutical compositions and hot melt extrudates. | 02-19-2015 |
20150071852 | FOXC1 ANTIBODIES AND METHODS OF THEIR USE - In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided. | 03-12-2015 |
20150071853 | NUCLEOTIDE AND PROTEIN SEQUENCES OF AN ANTIBODY DIRECTED AGAINST AN EPITOPE COMMON TO HUMAN ACIDIC AND BASIC FERRITINS, MONOCLONAL ANTIBODIES OR ANTIBODY-LIKE MOLECULES COMPRISING THESE SEQUENCES AND USE THEREOF - The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal. A method for delivering anti-ferritin antibodies or antibody-like molecules to cancerous lymph cells, pancreatic cells, lymphatic endothelium cells, and liver cells is also disclosed, as well as methods for treating pancreatic cancer, hepatocellular carcinomas, Kaposi's sarcoma and Hodgkin's lymphoma. | 03-12-2015 |
20150071854 | Human Monoclonal Antibodies Against Hendra and Nipah Viruses - The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 03-12-2015 |
20150104384 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES - The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds. | 04-16-2015 |
20150104385 | RADIO-PHARMACEUTICAL COMPLEXES - A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor. Methods of treatment utilising such complexes and methods of formation of such complexes are provided. | 04-16-2015 |
20150353636 | HUMAN IGG1 FC REGION VARIANTS AND USES THEREOF - Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC). | 12-10-2015 |
20160030606 | RADIO-LABELLED ANTIBODY FRAGMENTS FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER - The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (V | 02-04-2016 |
20160083361 | INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF - Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model. In still further aspects, the disclosed subject matter relates to methods for treating oncological and inflammatory disorders in a patient. For example, disclosed herein are methods whereby an effective amount of a compound or composition disclosed herein is administered to a patient having an oncological disorder, for example B-cell chronic lymphocytic leukemia (CLL), and who is in need of treatment thereof. XBP-1 deficiency causes leukemic cells to acquire phenotypes that are disadvantageous for their survival, such as compromised BCR signaling capability and increased surface expression of S1 P1. | 03-24-2016 |
20160101199 | METHOD FOR UPREGULATING ANTIGEN EXPRESSION - The present invention relates to radioimmunoconjugates that are capable of upregulating expression of one or more antigens. The upregulated antigens can be the antigens that are targeted by the radioimmunoconjugates or different antigens expressed on the same cells. The present invention also relates to methods of treating cancer and diseases and disorders of the immune system by utilizing this enhanced expression of antigens. | 04-14-2016 |
20160130328 | Pathogen Binding Agents Conjugated to Radioisotopes and Uses in Imaging and Therapeutic Applications - This disclosure relates to binding agents specific for the envelope protein of a virus, e.g., lentivirus, wherein the binding agent is conjugated to a molecule with a radioisotope or positron-emitting radionuclide. In certain embodiments, the disclosure relates to methods of imaging a virus or other pathogen within the body of a subject using binding agents disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing a viral or other pathogenic infection by administering pharmaceutical composition containing radioactive binding agents disclosed herein. | 05-12-2016 |
20160151515 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | 06-02-2016 |
20160159910 | ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same. | 06-09-2016 |
20160166718 | COMPOSITIONS AND METHODS FOR DETECTING OR ELIMINATING SENESCENT CELLS TO DIAGNOSE OR TREAT DISEASE | 06-16-2016 |
20160199509 | Cancer Treatment Comprising Therapeutics That Bind to Phosphatidylserine | 07-14-2016 |
20160250350 | DELIVERY SYSTEM FOR CYTOTOXIC DRUGS BY BISPECIFIC ANTIBODY PRETARGETING | 09-01-2016 |
20160250360 | RADIOPHARMACEUTICAL SOLUTIONS WITH ADVANTAGEOUS PROPERTIES | 09-01-2016 |